Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
348 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
Conditions: Refractory or Recurrent Hypermutated Malignancies;   Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
Intervention: Drug: Nivolumab
2 Not yet recruiting Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
Conditions: Melanoma and Other Malignant Neoplasms of Skin;   Leptomeningeal Disease
Intervention: Drug: Nivolumab
3 Recruiting A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Condition: Renal Cell Carcinoma
Intervention: Drug: nivolumab
4 Not yet recruiting Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Conditions: Urothelial Carcinoma;   Bladder Cancer
Interventions: Drug: Nivolumab in combination with Urelumab;   Drug: Nivolumab monotherapy
5 Recruiting Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: Nivolumab
6 Recruiting Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
Condition: Carcinoma, Renal Cell
Interventions: Drug: Tivozanib;   Drug: Nivolumab
7 Not yet recruiting Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
Condition: Bladder Cancer
Interventions: Drug: Nivolumab;   Behavioral: Questionnaires
8 Not yet recruiting Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Conditions: Thymoma Type B3;   Thymic Carcinoma
Intervention: Drug: Nivolumab
9 Recruiting Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Biological: Nivolumab/Ipilimumab
10 Not yet recruiting Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Nivolumab
11 Recruiting Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Conditions: Biliary Tract Cancer;   Biliary Tract Neoplasms
Intervention: Drug: Nivolumab
12 Not yet recruiting Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Condition: Oral Cavity SCC
Intervention: Drug: Nivolumab
13 Recruiting Nivolumab With DC Vaccines for Recurrent Brain Tumors
Conditions: Malignant Glioma;   Astrocytoma;   Glioblastoma
Interventions: Drug: nivolumab;   Biological: DC
14 Not yet recruiting Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
Condition: Soft Tissue Sarcomas
Interventions: Biological: Nivolumab;   Drug: Pazopanib
15 Recruiting Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Conditions: Melanoma;   Renal Cell Carcinoma;   Non-Small Cell Lung Cancer
Intervention: Drug: HBI-8000 in combination with nivolumab
16 Recruiting Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases
Conditions: Melanoma;   Brain Metastasis
Intervention: Drug: Nivolumab
17 Not yet recruiting Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient
Condition: Nivolumab Treatment in Expanded Use in Real World
Intervention: Drug: Nivolumab 10 MG/ML
18 Recruiting MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)
Conditions: Malignant Neoplasms of Urinary Tract;   Other Disorders of Kidney and Ureter;   Renal Cell Carcinoma
Interventions: Drug: MGCD516;   Drug: Nivolumab
19 Recruiting A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors
Conditions: Carcinoma,Non-Small-Cell Lung;   Carcinoma, Renal Cell;   Melanoma
Intervention: Drug: Combination of NKTR-214 + nivolumab
20 Recruiting Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse
Conditions: Leukemia;   Acute Myeloid Leukemia
Intervention: Drug: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.